Search research articles
Contact Us
Filters
Showing results (91-100 of 108) with videos related to
Page
of 11
Sort By:
Science Advances
|
February 1, 2021
1-Methylnicotinamide is an immune regulatory metabolite in human ovarian cancer
Marisa K Kilgour, Sarah MacPherson, Lauren G Zacharias, et al.
Immunohorizons
|
May 23, 2023
SRF617 Is a Potent Inhibitor of CD39 with Immunomodulatory and Antitumor Properties
Michael C Warren, Stephan Matissek, Matthew Rausch, et al.
Nature Medicine
|
June 25, 2026
Neoadjuvant stereotactic body radiation therapy with durvalumab and oleclumab in ER<sup>+</sup>HER2<sup>-</sup> breast cancer: a randomized phase 2 trial
Alex De Caluwé, Isabelle Desmoulins, Kim Cao, et al.
The Journal of Clinical Investigation
|
February 13, 2019
Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers
Tina Gruosso, Mathieu Gigoux, Venkata Satya Kumar Manem, et al.
Molecular Cell
|
February 20, 2021
DNA hypomethylating agents increase activation and cytolytic activity of CD8<sup>+</sup> T cells
Helen Loo Yau, Emma Bell, Ilias Ettayebi, et al.
Cell Reports
|
March 2, 2025
The NF1 tumor suppressor regulates PD-L1 and immune evasion in melanoma
Diana Berry, Dan Moldoveanu, Shivshankari Rajkumar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 30, 2020
Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma
Ailin Lepletier, Jason Madore, Jake S O'Donnell, et al.
Cancer Discovery
|
June 20, 2022
IL27 Signaling Serves as an Immunologic Checkpoint for Innate Cytotoxic Cells to Promote Hepatocellular Carcinoma
Turan Aghayev, Aleksandra M Mazitova, Jennifer R Fang, et al.
Nature Communications
|
December 12, 2023
Author Correction: Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial
Laurence Buisseret, Delphine Loirat, Philippe Aftimos, et al.
Nature Communications
|
November 3, 2023
Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial
Laurence Buisseret, Delphine Loirat, Philippe Aftimos, et al.
Page
of 11
Search research articles
Search
Showing results (91-100 of 108) with videos related to
Sort By:
Page
of 11
Science Advances
|
February 1, 2021
1-Methylnicotinamide is an immune regulatory metabolite in human ovarian cancer
Marisa K Kilgour, Sarah MacPherson, Lauren G Zacharias, et al.
Immunohorizons
|
May 23, 2023
SRF617 Is a Potent Inhibitor of CD39 with Immunomodulatory and Antitumor Properties
Michael C Warren, Stephan Matissek, Matthew Rausch, et al.
Nature Medicine
|
June 25, 2026
Neoadjuvant stereotactic body radiation therapy with durvalumab and oleclumab in ER<sup>+</sup>HER2<sup>-</sup> breast cancer: a randomized phase 2 trial
Alex De Caluwé, Isabelle Desmoulins, Kim Cao, et al.
The Journal of Clinical Investigation
|
February 13, 2019
Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers
Tina Gruosso, Mathieu Gigoux, Venkata Satya Kumar Manem, et al.
Molecular Cell
|
February 20, 2021
DNA hypomethylating agents increase activation and cytolytic activity of CD8<sup>+</sup> T cells
Helen Loo Yau, Emma Bell, Ilias Ettayebi, et al.
Cell Reports
|
March 2, 2025
The NF1 tumor suppressor regulates PD-L1 and immune evasion in melanoma
Diana Berry, Dan Moldoveanu, Shivshankari Rajkumar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 30, 2020
Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma
Ailin Lepletier, Jason Madore, Jake S O'Donnell, et al.
Cancer Discovery
|
June 20, 2022
IL27 Signaling Serves as an Immunologic Checkpoint for Innate Cytotoxic Cells to Promote Hepatocellular Carcinoma
Turan Aghayev, Aleksandra M Mazitova, Jennifer R Fang, et al.
Nature Communications
|
December 12, 2023
Author Correction: Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial
Laurence Buisseret, Delphine Loirat, Philippe Aftimos, et al.
Nature Communications
|
November 3, 2023
Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial
Laurence Buisseret, Delphine Loirat, Philippe Aftimos, et al.
Page
of 11